Jun 22, 2020
Aethlon Medical Presents Hemopurifier® Data at the American Association for Cancer Research 2020 Annual Meeting
Jun 18, 2020
Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients
Mar 24, 2020
Aethlon Announces Issuance of European Patent for the Hemopurifier® in Cancer
Feb 24, 2020
Securities and Exchange Commission (SEC) Order for Halt in trading of Aethlon Medical Stock Expires
Feb 10, 2020
Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
Feb 10, 2020
Securities and Exchange Commission (SEC) Order for Halt in trading of Aethlon Medical (NASDAQ:AEMD) Stock
Feb 06, 2020
Aethlon Medical To Release Third Quarter Financial Results and Host Conference Call on February 10, 2020
Jan 17, 2020
Aethlon Medical Announces $3.77 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Dec 17, 2019
Aethlon Medical Announces Closing of $5 Million Public Offering
Dec 13, 2019
Aethlon Medical Announces Pricing of $5 Million Public Offering
Nov 01, 2019
Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
Oct 14, 2019
Aethlon Announces Reverse Stock Split
Oct 07, 2019
Aethlon Medical Announces FDA Approval Of IDE For Oncology Indications
Oct 03, 2019
Aethlon Medical Receives Extension from Nasdaq to Regain Compliance with Continued Listing Requirements
Sep 24, 2019
Aethlon Announces Collaboration to Identify Exosomes Involved in Cancer Progression and Treatment Resistance
Sep 16, 2019
Aethlon Medical Receives National Cancer Institute Contract Award
Aug 07, 2019
Aethlon Medical To Release First Quarter Financial Results and Host Conference Call on August 14, 2019
Jul 01, 2019
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
Jul 01, 2019
Aethlon Medical, Inc. and SeaStar Medical, Inc. Announce Strategic Joint Cross-Licensing Agreement
Jun 19, 2019
Aethlon Medical To Release Fiscal Year End Financial Results and Host Conference Call on July 1, 2019